Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Mehreen S. Datoo(University of Oxford), Nsajigwa Misidai, Philip Bejon(Nuffield Orthopaedic Centre), Alassane Dicko(Ministère de la Santé et de l'Hygiène Publique), Mahamadou Kaya, Sunil Gairola(Serum Institute of India (India)), Seydina O Maguiraga, Halidou Tinto(Institut de Recherche en Sciences de la Santé), Ismaila Théra, Fernando Ramos Lopez(University of Oxford), Daniel Chandramohan(London School of Hygiene & Tropical Medicine), Brian Greenwood(London School of Hygiene & Tropical Medicine), Issaka Sagara(Inserm), Ally Olotu(Ifakara Health Institute), Katie Ewer(University of Oxford), Emma Beaumont(London School of Hygiene & Tropical Medicine), Djibrilla Issiaka, Adrian V. S. Hill(Jenner Institute), Yves Daniel Compaoré, Alison M. Lawrie(University of Oxford), Mamoudou Samassekou, Sophie Weston(University of Oxford), Lisa Stockdale(University of Oxford), Soumaïla Diarra, Mainga Hamaluba(Universidade Federal do Rio Grande do Sul), Hama Yalcouye(Kenya Medical Research Institute), Oumar Attaher(University of Bamako), Oumar M Dicko(Université des Sciences, des Techniques et des Technologies de Bamako), Amadou Tapily(University of Bamako), Kalifa Diarra, Hamtandi Magloire Natama(Centre National de la Recherche Scientifique et Technologique), Umesh Shaligram(Serum Institute of India (India)), Makonon Diallo, Prasad S. Kulkarni(Serum Institute of India (India)), Mwajuma Chemba(Ifakara Health Institute), John Bradley(London School of Hygiene & Tropical Medicine), Sidi M. Niambele, Sandesh Bharati(Serum Institute of India (India)), Diallo Salou(Institut de Recherche en Sciences de la Santé), Sharon Omenda(Kenya Medical Research Institute), Yaya Sankaré, Rachel Roberts(University of Oxford), Almahamoudou Mahamar(University of Bamako), Mala Sylla, Amagana Dolo(University of Bamako), Youssoufa Sidibé(University of Bamako), Jean‐Bosco Ouédraogo(Institut de Recherche en Sciences de la Santé), Koualy Sanogo, Harish Rao(Serum Institute of India (India))
Cited by 345
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451